[
    {
        "id": 1,
        "drugName": "Metformin",
        "fdaApprovalDate": "1994-12-29",
        "primaryIndication": "Type 2 Diabetes",
        "mechanism": "AMPK activation, mTOR inhibition",
        "knownTargets": [
            "AMPK",
            "Complex I"
        ],
        "adverseEvents": [
            "GI distress",
            "Lactic acidosis (rare)"
        ],
        "pkSummary": "Oral bioavailability ~50-60%, Half-life 4-8 hours",
        "patentStatus": "Expired",
        "marketValue": "$2.3B annually"
    },
    {
        "id": 2,
        "drugName": "Sildenafil",
        "fdaApprovalDate": "1998-03-27",
        "primaryIndication": "Erectile Dysfunction, Pulmonary Hypertension",
        "mechanism": "PDE5 inhibition",
        "knownTargets": [
            "PDE5"
        ],
        "adverseEvents": [
            "Headache",
            "Flushing",
            "Visual disturbances"
        ],
        "pkSummary": "Oral bioavailability ~40%, Half-life 3-5 hours",
        "patentStatus": "Expired (2020)",
        "marketValue": "$1.8B annually"
    },
    {
        "id": 3,
        "drugName": "Thalidomide",
        "fdaApprovalDate": "1998-07-16",
        "primaryIndication": "Multiple Myeloma, Leprosy",
        "mechanism": "Immunomodulation, anti-angiogenic",
        "knownTargets": [
            "CRBN",
            "TNF-α"
        ],
        "adverseEvents": [
            "Teratogenicity",
            "Peripheral neuropathy",
            "DVT"
        ],
        "pkSummary": "Variable absorption, Half-life 5-7 hours",
        "patentStatus": "Active",
        "marketValue": "$900M annually"
    },
    {
        "id": 4,
        "drugName": "Aspirin",
        "fdaApprovalDate": "1950-01-01",
        "primaryIndication": "Pain, Inflammation, Cardiovascular Protection",
        "mechanism": "COX-1/COX-2 inhibition",
        "knownTargets": [
            "COX-1",
            "COX-2"
        ],
        "adverseEvents": [
            "GI bleeding",
            "Tinnitus"
        ],
        "pkSummary": "Rapid absorption, Half-life 15-20 minutes (aspirin), 2-3 hours (salicylate)",
        "patentStatus": "Public domain",
        "marketValue": "$1.2B annually"
    },
    {
        "id": 5,
        "drugName": "Propranolol",
        "fdaApprovalDate": "1967-11-13",
        "primaryIndication": "Hypertension, Angina, Arrhythmias",
        "mechanism": "β-adrenergic receptor antagonist",
        "knownTargets": [
            "β1",
            "β2 receptors"
        ],
        "adverseEvents": [
            "Bradycardia",
            "Fatigue",
            "Bronchospasm"
        ],
        "pkSummary": "Extensive first-pass metabolism, Half-life 3-6 hours",
        "patentStatus": "Expired",
        "marketValue": "$450M annually"
    },
    {
        "id": 6,
        "drugName": "Raloxifene",
        "fdaApprovalDate": "1997-12-10",
        "primaryIndication": "Osteoporosis, Breast Cancer Prevention",
        "mechanism": "Selective estrogen receptor modulator",
        "knownTargets": [
            "ER-α",
            "ER-β"
        ],
        "adverseEvents": [
            "Hot flashes",
            "DVT risk"
        ],
        "pkSummary": "Rapid absorption, Half-life 27-32 hours",
        "patentStatus": "Expired (2014)",
        "marketValue": "$680M annually"
    },
    {
        "id": 7,
        "drugName": "Valproic Acid",
        "fdaApprovalDate": "1978-02-28",
        "primaryIndication": "Epilepsy, Bipolar Disorder, Migraine",
        "mechanism": "HDAC inhibition, GABA enhancement",
        "knownTargets": [
            "HDAC",
            "GABA"
        ],
        "adverseEvents": [
            "Hepatotoxicity",
            "Teratogenicity",
            "Weight gain"
        ],
        "pkSummary": "Complete absorption, Half-life 9-16 hours",
        "patentStatus": "Expired",
        "marketValue": "$1.1B annually"
    },
    {
        "id": 8,
        "drugName": "Losartan",
        "fdaApprovalDate": "1995-04-14",
        "primaryIndication": "Hypertension, Diabetic Nephropathy",
        "mechanism": "Angiotensin II receptor antagonist",
        "knownTargets": [
            "AT1 receptor"
        ],
        "adverseEvents": [
            "Dizziness",
            "Hyperkalemia"
        ],
        "pkSummary": "Oral bioavailability ~33%, Half-life 2 hours (6-9 hours for active metabolite)",
        "patentStatus": "Expired (2010)",
        "marketValue": "$2.1B annually"
    },
    {
        "id": 9,
        "drugName": "Donepezil",
        "fdaApprovalDate": "1996-11-25",
        "primaryIndication": "Alzheimer's Disease",
        "mechanism": "Acetylcholinesterase inhibition",
        "knownTargets": [
            "AChE"
        ],
        "adverseEvents": [
            "Nausea",
            "Diarrhea",
            "Insomnia"
        ],
        "pkSummary": "Well absorbed, Half-life 70 hours",
        "patentStatus": "Expired (2010)",
        "marketValue": "$1.4B annually"
    },
    {
        "id": 10,
        "drugName": "Imatinib",
        "fdaApprovalDate": "2001-05-10",
        "primaryIndication": "Chronic Myeloid Leukemia",
        "mechanism": "BCR-ABL tyrosine kinase inhibition",
        "knownTargets": [
            "BCR-ABL",
            "c-KIT",
            "PDGFR"
        ],
        "adverseEvents": [
            "Edema",
            "Nausea",
            "Muscle cramps"
        ],
        "pkSummary": "Oral bioavailability ~98%, Half-life 18 hours",
        "patentStatus": "Expired (2015)",
        "marketValue": "$4.7B peak"
    }
]